Due to these diverse effects of EZH2 overexpression in tumor cells and TME-associated cells, the inhibition of EZH2 using epigenome-targeting agents may lead to a decrease in immunosuppression, thereby sensitizing tumors to immunotherapies. Here, EZH2 is linked to neoplasm.